TYK2 and systemic lupus erythematosus: Deucracitinib is the first FDA-approved oral TYK2 inhibitor for the treatment of moderate to severe plaque psoriasis.60 In SLE, there are promising results from a phase 2 study including 363 patients with active SLE.61 In this study, patients receiving 3 mg of deucracitinib twice daily met the primary endpoint, SRI-4 at week 32,61 while deucracitinib treated patients had higher frequencies of attainment of LLDAS, BICLA response and CLASI-50 and improvement in arthritis at week 48.61